Innovent and Roche sign collaboration and license agreement for IBI-3009

Jan. 2, 2025

Innovent Biologics Inc. has entered into a collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd. to advance the development of IBI-3009, a novel DLL3-targeted antibody-drug conjugate (ADC) candidate.

BioWorld Science License Cancer Antibody-drug conjugate Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for April 3, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 3, 2025.

Medtronic, Recor commence hostilities over RDN patents

BioWorld MedTech

The renal denervation patent wars are now in full swing, with Medtronic plc and Recor Medical LLC landing the first blow in this chapter of the med tech patent...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Illustration of Microglia cells (red) in Alzheimer´s disease

ADPD 2025: Emerging strategies fueling Alzheimer’s disease research

BioWorld Science

During the first oral sessions on Translational Drug Discovery at the 19th Alzheimer’s & Parkinson’s Diseases (ADPD) Conference, Beka Solomon from Tel Aviv...